Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare

Arthritis and Rheumatology

Volumn 66, Issue 7, 2014, Pages 1888-1899

  Munroe, Melissa E ^a   Vista, Evan S ^a,b   Guthridge, Joel M ^a   Thompson, Linda F ^a   Merrill, Joan T ^a   James, Judith A ^c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CHEMOKINE; CYTOKINE; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TH2 CELL;

ADAPTIVE IMMUNITY; ADULT; ANTIGENS, CD95; BIOLOGICAL MARKERS; CD40 LIGAND; CYTOKINES; FAS LIGAND PROTEIN; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84903453743     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38573     Document Type: Article

References (45)

1. Lam GK, Petri M,. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23: S120-32.
2. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-8.
3. Liu CC, Ahearn JM,. The search for lupus biomarkers. Best Pract Res Clin Rheumatol 2009; 23: 507-23.
4. Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al, on behalf of the BLISS-52 and BLISS-76 Study Groups. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013; 65: 2143-53.
5. Petri M, Singh S, Tesfasyone H, Malik A,. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009; 36: 2476-80.
6. Lau CS, Mak A,. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009; 5: 400-4.
7. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC,. Serum IL-6, TNFα, p55 srTNFα, p75srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999; 18: 17-22.
8. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007; 27: 461-6.
9. Gomez D, Correa PA, Gomez LM, Cadena J, Molina JF, Anaya JM,. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor α protective? Semin Arthritis Rheum 2004; 33: 404-13.
10. Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Takasaki Y, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999; 116: 169-73.
11. Shah K, Lee WW, Lee SH, Kim SH, Kang SW, Craft J, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R53.
12. Mok MY, Wu HJ, Lo Y, Lau CS,. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol 2010; 37: 2046-52.
13. Chen DY, Chen YM, Wen MC, Hsieh TY, Hung WT, Lan JL,. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012; 21: 1385-96.
14. Becker-Merok A, Eilertsen GO, Nossent JC,. Levels of transforming growth factor-β are low in systemic lupus erythematosus patients with active disease. J Rheumatol 2010; 37: 2039-45.
15. + regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 1549-58.
16. Golding A, Hasni S, Illei G, Shevach EM,. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum 2013; 65: 2898-906.
17. Bonelli M, von Dalwigk K, Savitskaya A, Smolen JS, Scheinecker C,. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. Ann Rheum Dis 2008; 67: 664-71.
18. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005; 175: 8392-400.
19. Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006; 27: 110-8.
20. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J,. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008; 17: 289-94.
21. + T cells in lupus patients. Clin Rheumatol 2010; 29: 1251-8.
22. Croft M, Benedict CA, Ware CF,. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013; 12: 147-68.
23. Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, et al. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Int Immunol 2009; 21: 237-43.
24. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK,. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-73.
25. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010; 12: R48.
26. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-9.
27. Espinosa G, Cervera R,. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Drugs Today (Barc) 2010; 46: 891-9.
28. Qin Q, Chang Y, Wang D, Wu Y, Zhang LL, Wei W,. TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis. Int Immunopharmacol 2011; 11: 2167-75.
29. Crowe SR, Merrill JT, Vista ES, Dedeke AB, Thompson DM, Stewart S, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum 2011; 63: 2396-406.
30. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
31. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
32. Stringer EA, Baker KS, Carroll IR, Montoya JG, Chu L, Maecker HT, et al. Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology. J Transl Med 2013; 11: 93.
33. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL,. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 2005; 66: 175-91.
34. Dossus L, Becker S, Achaintre D, Kaaks R, Rinaldi S,. Validity of multiplex-based assays for cytokine measurements in serum and plasma from "non-diseased" subjects: comparison with ELISA. J Immunol Methods 2009; 350: 125-32.
35. Hughes-Austin JM, Deane KD, Derber LA, Kolfenbach JR, Zerbe GO, Sokolove J, et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis 2013; 72: 901-7.
36. Arend WP,. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13: 323-40.
37. Chu VT, Enghard P, Schurer S, Steinhauser G, Rudolph B, Riemekasten G, et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2083-93.
38. Okamoto A, Fujio K, Okamura T, Yamamoto K,. Regulatory T-cell-associated cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011; 2011: 463412.
39. Doedens JR, Mahimkar RM, Black RA,. TACE/ADAM-17 enzymatic activity is increased in response to cellular stimulation. Biochem Biophys Res Commun 2003; 308: 331-8.
40. + regulatory T cells. Immunology 2011; 133: 426-33.
41. + regulatory T cells inhibits the induction of inflammatory mediators. J Immunol 2008; 180: 2747-51.
42. Mok CC, Ho LY, Fong LS, To CH,. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013; 72: 659-64.
43. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D,. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 2000; 27: 1681-5.
44. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012; 64: 1794-803.
45. Peabody JW, Strand V, Shimkhada R, Lee R, Chernoff D,. Impact of rheumatoid arthritis disease activity test on clinical practice. PLoS One 2013; 8: e63215.